Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50458 |
Name | juvenile myelomonocytic leukemia |
Definition | A myelodysplastic/myeloproliferative neoplasm that is characterized by the uncontrolled growth of monocytes. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myelodysplastic/myeloproliferative neoplasm juvenile myelomonocytic leukemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT01621477 | Phase II | Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | Terminated | USA | 0 |
NCT02564536 | Phase I | Decitabine + Pacritinib | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | Withdrawn | 0 | |
NCT02790515 | Phase II | Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim | Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | Active, not recruiting | USA | 0 |
NCT03190915 | Phase II | Trametinib | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03326921 | Phase I | Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT03843528 | Phase I | Azacitidine + Vorinostat | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | Recruiting | USA | 0 |
NCT05849662 | Phase Ib/II | Azacitidine + Cytarabine + Fludarabine + Trametinib Azacitidine + Trametinib | A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT06247787 | Phase I | Hydrocortisone Sodium Succinate + Methotrexate Leucovorin Cytarabine + Hydrocortisone Sodium Succinate Cytarabine + Fludarabine + Imetelstat | A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Recruiting | USA | 0 |